FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating Disorder
Research
The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.
Leave a Reply
Want to join the discussion?Feel free to contribute!